Tyler Stone Wealth Management raised its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 134.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 49,050 shares of the company's stock after purchasing an additional 28,125 shares during the quarter. Tyler Stone Wealth Management's holdings in Kenvue were worth $1,135,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of KVUE. Leo Wealth LLC increased its stake in shares of Kenvue by 0.3% in the third quarter. Leo Wealth LLC now owns 151,611 shares of the company's stock worth $3,507,000 after buying an additional 481 shares during the last quarter. Massmutual Trust Co. FSB ADV increased its position in shares of Kenvue by 6.2% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company's stock worth $194,000 after purchasing an additional 492 shares during the last quarter. Wolff Wiese Magana LLC increased its position in shares of Kenvue by 0.7% in the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company's stock worth $1,781,000 after purchasing an additional 501 shares during the last quarter. Marathon Capital Management raised its stake in shares of Kenvue by 0.3% in the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company's stock valued at $2,722,000 after purchasing an additional 514 shares in the last quarter. Finally, Poehling Capital Management INC. grew its stake in Kenvue by 0.5% in the second quarter. Poehling Capital Management INC. now owns 104,934 shares of the company's stock worth $1,908,000 after purchasing an additional 547 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts have issued reports on KVUE shares. Piper Sandler upped their price objective on Kenvue from $20.00 to $21.00 and gave the company a "neutral" rating in a research note on Monday, September 23rd. JPMorgan Chase & Co. upped their price target on Kenvue from $24.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, October 11th. Bank of America lifted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a report on Tuesday, October 22nd. UBS Group increased their target price on shares of Kenvue from $20.00 to $22.00 and gave the stock a "neutral" rating in a report on Wednesday, August 7th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of Kenvue from $23.00 to $24.00 and gave the company a "buy" rating in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $22.64.
Get Our Latest Research Report on Kenvue
Kenvue stock traded up $0.71 during midday trading on Friday, reaching $23.68. 16,635,437 shares of the stock traded hands, compared to its average volume of 16,248,485. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $23.72. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.69. The firm has a market cap of $45.35 billion, a price-to-earnings ratio of 40.83, a PEG ratio of 2.94 and a beta of 1.36. The firm has a fifty day moving average price of $22.65 and a two-hundred day moving average price of $20.54.
Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The company had revenue of $3.90 billion for the quarter, compared to analysts' expectations of $3.92 billion. During the same quarter in the previous year, the company posted $0.31 earnings per share. The business's revenue for the quarter was down .4% compared to the same quarter last year. On average, equities research analysts forecast that Kenvue Inc. will post 1.08 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be given a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a yield of 3.46%. Kenvue's dividend payout ratio (DPR) is presently 141.38%.
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.